Background: One developing strategy for the treatment of Erectile Dysfunction (ED) involves the utilization of noninvasive low intensity extracorporeal shockwave (LI-ESWT) therapy. This method shows promise in enhancing erectile function, while also demonstrating satisfactory levels of safety and efficacy. The objective of the present investigation was to assess the safety and effectiveness of LI-ESWT in comparison to phosphodiesterase type 5 inhibitor (PDE5i) treatment for males experiencing mild to moderate ED.
Methods and Patients: This prospective randomized controlled trial (RCT) was done on sixty male individuals with ED with mild to moderate ED degree (index of erectile function (IIEF 5) =twelve-sixteen), married with stable heterosexual relationship for more than six months, proved to had vasculogenic ED etiology and vasculogenic ED by doppler,. Patients were randomly categorized into two equal groups by (Block randomization). Group A: underwent LI ESWT and Group B: received sildenafil hundred mg on demand.
Results: There was a important development in Erectile Hardness Score (EHS), IIEF-5, self- esteem and relationship (SEAR) scores at the treatment of the first and third months of in both groups when compared with level of baseline. Indicate that there were no important variance among group A and group B in terms of the IIEF-5, EHS at follow-up and baseline.
Conclusions: The findings of the research indicate that Li-ESWT had comparable efficacy to sildenafil in terms of treatment outcomes, as assessed by IIEF-5, SHE questionnaire. The observed enhancements in the EHS and IIEF-5 measures indicate that both interventions effectively improved function of erectile.